Lifestyle

Daesang Cheongjeonwon Launches Three Low-Sugar Hongcho Products… Targets 30 Billion Won in Sales This Year

Expansion of Pomegranate and Stick-Type Products Overseas Expansion to Begin in Earnest in the Second Half of the Year

SIN SOO-JUNG
2026-06-16 08:49:32
[Edaily Reporter Shin Su-jeong] #Daesang Cheongjeonwon is launching additional new low-sugar red vinegar products and expanding its line of fermented health drinks.

Daesang Cheongjeonwon announced on the 16th that it will launch three new low-sugar red vinegar products: Low-Sugar Red Vinegar Pomegranate, Low-Sugar Pomegranate Sticks, and Low-Sugar Red Apple Sticks. The low-sugar red vinegar line has recorded cumulative sales of approximately 20 billion won in just over a year since its launch. Daesang has set a goal of achieving 30 billion won in sales for its low-sugar red vinegar line this year.

These new products are part of a low-sugar line with reduced sugar and calories. They utilize allulose produced in-house by Daesang and are formulated as functional foods containing resistant maltodextrin, which is known to help suppress post-meal blood sugar spikes and promote regular bowel movements.

The Low-Sugar Pomegranate Red Vinegar uses fruit-fermented vinegar made from Spanish pomegranate concentrate. It contains 3g of sugar and 37 kcal per 100g. Daesang explained that compared to regular drinking vinegar, it has reduced sugar by 74% and calories by 56%.

The stick-type products are individually packaged in 40ml single-serve portions. They are designed for convenience, allowing consumers to mix them with water, sparkling water, or milk. The line consists of two varieties: Low-Sugar Pomegranate and Low-Sugar Red Apple, with each stick containing approximately 17 kcal.

Following the launch of two low-sugar red vinegar products in May of last year, Daesang Cheongjeonwon introduced a low-sugar red vinegar suitable for both hot and cold beverages in December of the same year. With this new product launch, the company has added its signature pomegranate flavor to the low-sugar lineup and expanded it to include stick-type products.

Daesang plans to begin actively targeting overseas markets, such as Japan and Vietnam, starting in the second half of this year. The company’s strategy is to expand its product lineup in response to growing domestic demand for low-sugar beverages while simultaneously strengthening its overseas sales channels.

Go Bong-gwan, Team Leader of Daesang’s Sauce Team, stated, “Low-sugar red vinegar has already proven its growth potential as a fermented health drink that reduces sugar and calorie intake, recording cumulative sales of approximately 20 billion won just over a year after its launch.” He added, “We will continue to expand our portfolio to offer both great taste and convenience, while accelerating our expansion into global markets such as Japan and Vietnam to become a world-class fermented health drink brand.”

Meanwhile, Cheongjeonwon Hongcho was launched in 2005 and is celebrating its 21st anniversary this year. Daesang is expanding its Hongcho lineup to include low-sugar products, products suitable for both hot and cold beverages, and stick-type products.

Economy

Corporation

IT·Science

Economy

POSCO FUTURE M: Financial Metrics Improve Amid Earnings Rebound… Managing Investment Burden Remains a 'Challenge'

“Credit Checkpoint” is a column that assesses the credit rating risks of companies preparing to issue corporate bonds by examining their financial structure and cash flow. It evaluates a company’s sho…
2026-11-03 19:42:04

Corporation

Department Stores Retain Only Their Most Profitable Locations… Accelerating 'Selective Focus'

The restructuring of department store locations is gaining momentum. As online shopping has become part of everyday life, the unique experiences offered exclusively by physical spaces—such as cultural…
2026-11-03 17:18:34

IT·Science

Voronoi, Inc.: Release Schedule for Follow-up Data on the C797S Undecided

Voronoi, Inc. avoided providing specific details regarding why only 8 out of 15 patients in the C797X variant patient group were included in the efficacy evaluation. The company also did not disclose …
2026-11-03 19:12:02